Thank you for the question.
I work in a world where our members also manufacture drugs, for example, and natural health products. For this type of efficiency and this type of leveraging of other decisions from other trusted regulators, I think if folks had a better understanding of how often the same data is reviewed for multiple products in multiple jurisdictions that arrive at the same outcome, the impetus there is not only in terms of market access, which of course from our perspective is the important issue, but also in terms of the resources being churned up in government. It's also about the opportunities perhaps for regulators to specialize. It's the idea that, rather than everybody doing the same thing over and over again, regulators who are collaborating and co-operative can find ways to reduce the amount of duplication that happens in that space.
I guess that's the general principle I would point to that we would love to see.